X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (29017) 29017
Publication (3226) 3226
Book Review (863) 863
Book Chapter (264) 264
Book / eBook (256) 256
Conference Proceeding (33) 33
Dissertation (28) 28
Newspaper Article (22) 22
Newsletter (10) 10
Data Set (7) 7
Magazine Article (7) 7
Trade Publication Article (2) 2
Transcript (2) 2
Web Resource (2) 2
Paper (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19078) 19078
index medicus (18685) 18685
animals (13418) 13418
female (6921) 6921
male (6782) 6782
oncology (6496) 6496
mice (6440) 6440
cancer (5661) 5661
research (5510) 5510
angiogenesis (5066) 5066
medicine (4747) 4747
expression (4616) 4616
research article (4523) 4523
proteins (4333) 4333
signal transduction (4094) 4094
multidisciplinary sciences (4002) 4002
gene expression (3881) 3881
inflammation (3856) 3856
health aspects (3751) 3751
vascular endothelial growth factor (3722) 3722
rodents (3509) 3509
kinases (3492) 3492
science (3482) 3482
care and treatment (3375) 3375
cell biology (3363) 3363
apoptosis (3298) 3298
physiological aspects (3084) 3084
endothelial growth-factor (3069) 3069
review (2994) 2994
middle aged (2957) 2957
pharmacology & pharmacy (2954) 2954
tumors (2942) 2942
receptor (2718) 2718
biology (2668) 2668
medicine, research & experimental (2654) 2654
rats (2645) 2645
metastasis (2599) 2599
genetic aspects (2595) 2595
cytokines (2490) 2490
cell line, tumor (2487) 2487
article (2476) 2476
immunology (2470) 2470
aged (2451) 2451
biochemistry & molecular biology (2401) 2401
antineoplastic agents - therapeutic use (2378) 2378
adult (2343) 2343
activation (2305) 2305
receptors (2247) 2247
physiology (2199) 2199
development and progression (2155) 2155
analysis (2131) 2131
studies (2088) 2088
disease models, animal (1979) 1979
cells (1958) 1958
in-vivo (1925) 1925
chemotherapy (1886) 1886
signal transduction - drug effects (1877) 1877
cells, cultured (1846) 1846
angiogenesis inhibitors - therapeutic use (1843) 1843
risk factors (1802) 1802
cell proliferation (1782) 1782
breast cancer (1760) 1760
mice, inbred c57bl (1712) 1712
phosphorylation (1710) 1710
growth factors (1665) 1665
growth-factor receptor (1651) 1651
treatment outcome (1630) 1630
ligands (1624) 1624
immunohistochemistry (1591) 1591
inhibition (1556) 1556
oxidative stress (1512) 1512
medical research (1509) 1509
cancer therapies (1504) 1504
in-vitro (1500) 1500
bevacizumab (1480) 1480
prognosis (1466) 1466
stem cells (1453) 1453
therapy (1450) 1450
biochemistry (1433) 1433
gene-expression (1415) 1415
drug therapy (1401) 1401
vascular endothelial growth factor a - metabolism (1393) 1393
endothelial cells (1381) 1381
vegf (1344) 1344
endothelium (1335) 1335
diabetes (1329) 1329
cell proliferation - drug effects (1321) 1321
growth (1290) 1290
disease (1289) 1289
antineoplastic agents - pharmacology (1276) 1276
pathogenesis (1274) 1274
nf-kappa-b (1245) 1245
hypertension (1237) 1237
cell growth (1235) 1235
pathology (1234) 1234
patients (1197) 1197
mutation (1195) 1195
signaling (1187) 1187
breast-cancer (1185) 1185
vascular endothelial growth factor a - antagonists & inhibitors (1185) 1185
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (178) 178
Online Resources - Online (12) 12
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
UofT at Mississauga - Stacks (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
UTL at Downsview - May be requested (4) 4
UofT at Scarborough - Stacks (3) 3
Dentistry (Harry R Abbott) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (29257) 29257
French (82) 82
Japanese (61) 61
German (48) 48
Spanish (34) 34
Chinese (24) 24
Polish (15) 15
Hungarian (14) 14
Russian (9) 9
Portuguese (7) 7
Korean (6) 6
Italian (5) 5
Czech (3) 3
Swedish (3) 3
Arabic (2) 2
Danish (2) 2
Dutch (2) 2
Hebrew (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
Ophthalmology, ISSN 0161-6420, 2014, Volume 121, Issue 11, pp. 2247 - 2254
Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 369 - 13
Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suffering from wet age-related macular degeneration (AMD), particularly... 
CENTRAL SEROUS CHORIORETINOPATHY | DECORIN | CELLS | ANGIOGENESIS | ENDOTHELIAL-GROWTH-FACTOR | BEVACIZUMAB | MACROPHAGES | SPIRONOLACTONE | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | RANIBIZUMAB | Receptors, Mineralocorticoid - genetics | Prospective Studies | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Receptors, Mineralocorticoid - metabolism | Humans | Rats, Long-Evans | Recombinant Fusion Proteins - therapeutic use | Male | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor A - genetics | Macular Degeneration - drug therapy | Microspheres | Choroidal Neovascularization - drug therapy | Choroidal Neovascularization - pathology | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Choroid - pathology | Spironolactone - therapeutic use | Choroid - drug effects | Gene Expression | Choroid - metabolism | Drug Compounding - methods | Mice, Transgenic | Treatment Outcome | Mineralocorticoid Receptor Antagonists - therapeutic use | Macular Degeneration - metabolism | Pilot Projects | Animals | Choroidal Neovascularization - metabolism | Macular Degeneration - genetics | Aged | Mice | Choroidal Neovascularization - genetics | Macular Degeneration - pathology | Stresses | Time resolved | Calcium channels | Starvation | Yeast | Environmental changes | Crosslinking | Imposition | Gene expression | Ribonucleic acid--RNA | Age related diseases | Stress | Proteins | Transcription termination | RNA-binding protein | Kinetics | Life Sciences | Human health and pathology | Pharmacology | Sensory Organs | Pharmaceutical sciences
Journal Article
Journal Article
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2016, Volume 169, pp. 68 - 72
Abstract Purpose To investigate a certain set of methodological limitations in published anti-VEGF randomized controlled trials (RCT). Design Descriptive... 
Ophthalmology | OPHTHALMOLOGY | MANAGEMENT | INTRAVITREAL BEVACIZUMAB | EFFICACY | SAMPLE-SIZE CALCULATIONS | RANIBIZUMAB | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Aptamers, Nucleotide - therapeutic use | Drug-Related Side Effects and Adverse Reactions - etiology | Male | Treatment Outcome | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Drug-Related Side Effects and Adverse Reactions - epidemiology | Randomized Controlled Trials as Topic | Ranibizumab - adverse effects | Angiogenesis Inhibitors - therapeutic use | Female | Angiogenesis Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions - diagnosis | Databases, Factual | Physiological aspects | Medical colleges | Vascular endothelial growth factor | Analysis | Eye diseases | Endothelial growth factors | Cataracts | Diabetic retinopathy | Internal medicine | Funding | Clinical trials | Impact factors | Studies | Macular degeneration | Medicine | Reading | Archives & records | Surgery | Journals | Diabetes | Drug dosages | Research methodology | Age
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2013, Volume 156, Issue 1, pp. 23 - 28.e2
Journal Article